Drug Trial Radar · NCT01708590
Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
Last checked: Nov 20, 2026Latest source record: Jan 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
661
Actual
Start
Aug 2012
Primary completion
May 2014
Study completion Aug 2015
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 17, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses.
Conditions
- Psoriasis
Interventions
210 mg brodalumabDrug
210 mg brodalumab administered subcutaneous (SC)
140 mg brodalumabDrug
140 mg brodalumab administered subcutaneous (SC)
placeboDrug
Placebo administered subcutaneous (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75 at Week 12Time frame: 0-12 weeks
- Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12Time frame: 0 - 12 Weeks
Locations
78 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Bakersfield, California
Research Site
Encino, California
Research Site
Los Angeles, California
Research Site
San Diego, California
Research Site
San Francisco, California
Research Site
San Ramon, California
Research Site
Santa Monica, California
Research Site
Alpharetta, Georgia
Research Site
West Dundee, Illinois
Research Site
Richmond, Kentucky
Research Site
Columbia, Maryland
Research Site
Boston, Massachusetts
Research Site
Fort Gratiot, Michigan
Research Site
St Louis, Missouri
Research Site
St Louis, Missouri
Research Site
St Louis, Missouri
Research Site
Omaha, Nebraska
Research Site
Buffalo, New York
Research Site
Forest Hills, New York
Research Site
Rochester, New York
Research Site
Stony Brook, New York
Research Site
Wilmington, North Carolina
Research Site
Cleveland, Ohio
Research Site
Portland, Oregon
Research Site
Rapid City, South Dakota
Research Site
Goodlettsville, Tennessee
Research Site
Nashville, Tennessee
Research Site
Arlington, Texas
Research Site
Austin, Texas
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
San Antonio, Texas
Research Site
Surrey, British Columbia, Canada
Research Site
Moncton, New Brunswick, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Greater Sudbury, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
North Bay, Ontario, Canada
Research Site
Waterloo, Ontario, Canada
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.